Ocular Therapeutix (OCUL) Misses Q2 EPS by 4c

Ocular Therapeutix (NASDAQ: OCUL) reported Q2 EPS of ($0.25), $0.04 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $11.7 million versus the consensus estimate of $11.6 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• XPeng stock falls on Q2 results miss; robotics arm raises $900 mln
• H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)